This is a randomized, open-label, interventional, controlled study to determine the effects
of Zaltrap on Neovascularized Wet Macular Degeneration as compared to the control
anti-vascular endothelial growth factor ("anti-VEGF") injections (bevacizumab, ranibizumab,
or aflibercept).